<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05019586</url>
  </required_header>
  <id_info>
    <org_study_id>University Hosp North Norway</org_study_id>
    <nct_id>NCT05019586</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori Resistance</brief_title>
  <acronym>CRIHEP</acronym>
  <official_title>Helicobacter Pylori Resistance. A Study of Morbidity, Immunological and Clinical Phenotypes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of North Norway</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of the study was to characterize the morbidity, immunological, microbiolical&#xD;
      and clinical phenotypes of patients with treated- resistance to Helicobacter pylori (HP)&#xD;
      infection, and the effect of triple therapy including the levofloxacin. Control groups were&#xD;
      newly diagnosed, previously infected and never infected HP patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See Nestegard O, et al. PLOS ONE | https://doi.org/10.1371/journal.pone.0238944 September 23,&#xD;
      2020&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2010</start_date>
  <completion_date type="Actual">July 10, 2020</completion_date>
  <primary_completion_date type="Actual">July 10, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterization of patients with chronic HP infection resistant to previous conventional triple therapy</measure>
    <time_frame>2010-2012</time_frame>
    <description>Clinical data including endoscopy, histology, microbiological data including resistance measurements, immunological data (mucosal tranacrips), effect of triple therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endoscopy</measure>
    <time_frame>2010-2012</time_frame>
    <description>endoscopic description of mucosa bye endoscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Histology</measure>
    <time_frame>2010-2012</time_frame>
    <description>Histological characterizations of inflammation (Sydney) of gastric mucosa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunology</measure>
    <time_frame>2010-2012</time_frame>
    <description>Immunological mucosal characterizations of pro- and antiinflammatory cytokine transcript (PCR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HP microbiology</measure>
    <time_frame>2010-2012</time_frame>
    <description>HP microbiology sensitivity to metronidazol, amoxicillin, clarithromycine, levofloxacin and tetracycline</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">185</enrollment>
  <condition>Helicobacter Pylori Resistance</condition>
  <arm_group>
    <arm_group_label>Helicobacter pylori resistance</arm_group_label>
    <description>Patients with treatment resistance to Helicobacter pylori treatment registered at GI-unites from 1990-2012 and included from 2010 to 2012. These patients were treated with a triple therapy of levofloxacin, amoxicillin and proton inhibitor for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Newly diagnosed Helicobacter pylori</arm_group_label>
    <description>Patients with newly diagnosed Helicobacter pylori infection from 2010-2012.These patients were treated with a triple therapy of clarithromycin, amoxicillin and proton inhibitor for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Previously eradicated Helicobacter pylori infection</arm_group_label>
    <description>Patients with previously Helicobacter pylori infection included from 2010-2012.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Never Helicobacter pylori infection</arm_group_label>
    <description>Patients with previously Helicobacter pylori infection included from 2010-2012.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levofloxacin, amoxicillin, clarithromycin</intervention_name>
    <description>Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days</description>
    <arm_group_label>Helicobacter pylori resistance</arm_group_label>
    <arm_group_label>Newly diagnosed Helicobacter pylori</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      RNA measure of mucosal transcripts, mucosal histology, cultures including antibiotic&#xD;
      sensitivity to HP from mucosal biopsies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Patients referred to Gastrointestinal (GI) unite in the time periode from 1990 to 2010&#xD;
             and defined as resistant to triple Helicobacter pylori (HP) treatment&#xD;
&#xD;
          2. Patients referred to GI unite in the time periode from 2010 to 2012 due to opper GI&#xD;
             complaints. Included were patients a) newly diagnosed HP, b) previously successful&#xD;
             triple HP therapy, and c) never HP infected&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients referred to a GI- unite with upper GI complains and performing an upper endoscopy&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with severe chronic diseases and not willing to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Florholmen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gastroenterology, Norwegian Artic University/Universiuty of Troms√∏, Norway</affiliation>
  </overall_official>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 14, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of North Norway</investigator_affiliation>
    <investigator_full_name>Jon Florholmen</investigator_full_name>
    <investigator_title>professor, MD</investigator_title>
  </responsible_party>
  <keyword>Gastrointestinal Symptom Rating Scale, Helicobacter pylori resistance, levofloxacin, Sydney score</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

